Finch Therapeutics Group, Inc.

General Information

We are a clinical-stage microbiome therapeutics company leveraging our Human-First Discovery platform to develop a novel class of orally administered biological drugs. The microbiome consists of trillions of microbes that live symbiotically in and on every human and are essential to our health. When key microbes are lost, the resulting dysbiosis can increase susceptibility to immune disorders, infections, neurological conditions, cancer and other serious diseases. We are developing novel therapeutics designed to deliver missing microbes and their clinically relevant biochemical functions to correct dysbiosis and the diseases that emerge from it. Our Human-First Discovery platform uses reverse translation to identify diseases of dysbiosis and to design microbiome therapeutics that address them.

Our lead product candidate, CP101, delivers a complete microbiome and is being developed initially for the treatment of patients with recurrent Clostridioides difficile infection, or CDI. In June 2020, we reported positive topline data from our first of two pivotal trials in recurrent CDI, and we plan to initiate a Phase 3 clinical trial, which we refer to as PRISM4, as our second pivotal trial of CP101 for recurrent CDI in mid-2021. Although we need to generate additional data confirming safety and efficacy to support regulatory approval of CP101 for the treatment of recurrent CDI, we believe data from our pivotal, Phase 2 clinical trial with CP101 validates our platform, positioning us to initiate new clinical trials in at least three new indications over the next 18 months, including chronic hepatitis B virus, or HBV, autism spectrum disorder, or ASD, and ulcerative colitis. (**Revenue and net loss figures are for the year ended Dec. 31, 2020.)

(Note: Finch Therapeutics upsized its IPO at pricing on March 18, 2021: 7.5 million shares, up from 6.3 million in the prospectus, were priced at $17 – the high end of its $15-to-$17 range – to raise $127.5 million.)

Employees: 131
Founded: 2014
Contact Information
Address 200 Inner Belt Road, Suite 400 Somerville, Massachusetts 02143
Phone Number (617) 229-6499
Web Address
View Prospectus: Finch Therapeutics Group, Inc.
Financial Information
Market Cap $734.4mil
Revenues $7.72 mil (last 12 months)
Net Income $-39.34 mil (last 12 months)
IPO Profile
Symbol FNCH
Exchange NASDAQ
Shares (millions): 7.5
Price range $17.00 - $17.00
Est. $ Volume $127.5 mil
Manager / Joint Managers BofA Securities/Jefferies/Evercore
CO-Managers -
Expected To Trade: 3/19/2021
Status: Priced
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change